CN101060844B - 包含嘧啶的nnrti和rt抑制剂的组合 - Google Patents

包含嘧啶的nnrti和rt抑制剂的组合 Download PDF

Info

Publication number
CN101060844B
CN101060844B CN2004800254267A CN200480025426A CN101060844B CN 101060844 B CN101060844 B CN 101060844B CN 2004800254267 A CN2004800254267 A CN 2004800254267A CN 200480025426 A CN200480025426 A CN 200480025426A CN 101060844 B CN101060844 B CN 101060844B
Authority
CN
China
Prior art keywords
tmc278
hiv
reverse transcriptase
combination
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN2004800254267A
Other languages
English (en)
Chinese (zh)
Other versions
CN101060844A (zh
Inventor
P·史脱夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen R&D Ireland ULC
Original Assignee
Tibotec Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34280181&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101060844(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharmaceuticals Ltd filed Critical Tibotec Pharmaceuticals Ltd
Publication of CN101060844A publication Critical patent/CN101060844A/zh
Application granted granted Critical
Publication of CN101060844B publication Critical patent/CN101060844B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2004800254267A 2003-09-03 2004-09-03 包含嘧啶的nnrti和rt抑制剂的组合 Expired - Lifetime CN101060844B (zh)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US49977103P 2003-09-03 2003-09-03
EP03103275.8 2003-09-03
EP03103275 2003-09-03
US60/499,771 2003-09-03
EP03103319 2003-09-08
EP03103319.4 2003-09-08
EP03103335 2003-09-10
EP03103335.0 2003-09-10
EP03103668.4 2003-10-02
EP03103668 2003-10-02
US50848603P 2003-10-03 2003-10-03
US60/508,486 2003-10-03
PCT/EP2004/052028 WO2005021001A1 (en) 2003-09-03 2004-09-03 Combinations of a pyrimidine containing nnrti with rt inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN2011102800883A Division CN102319433A (zh) 2003-09-03 2004-09-03 包含嘧啶的nnrti和rt抑制剂的组合

Publications (2)

Publication Number Publication Date
CN101060844A CN101060844A (zh) 2007-10-24
CN101060844B true CN101060844B (zh) 2012-01-04

Family

ID=34280181

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800254267A Expired - Lifetime CN101060844B (zh) 2003-09-03 2004-09-03 包含嘧啶的nnrti和rt抑制剂的组合

Country Status (24)

Country Link
US (9) US20080200435A1 (enExample)
EP (1) EP1663240B2 (enExample)
JP (3) JP5507791B2 (enExample)
KR (1) KR20060090658A (enExample)
CN (1) CN101060844B (enExample)
AP (1) AP2109A (enExample)
AU (5) AU2004268390B2 (enExample)
BE (1) BE2015C053I2 (enExample)
CA (1) CA2537095C (enExample)
CY (5) CY2015040I2 (enExample)
FI (1) FI1663240T4 (enExample)
FR (5) FR15C0071I2 (enExample)
HR (1) HRP20150798T4 (enExample)
HU (5) HUS1500054I1 (enExample)
IL (2) IL173438A (enExample)
LT (2) LTPA2016045I1 (enExample)
LU (3) LU92853I2 (enExample)
MX (1) MXPA06002437A (enExample)
MY (1) MY169670A (enExample)
NL (2) NL300781I1 (enExample)
NO (6) NO334877B1 (enExample)
NZ (1) NZ545306A (enExample)
PL (1) PL1663240T5 (enExample)
WO (1) WO2005021001A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8101629B2 (en) 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AU2003266413B2 (en) 2002-08-09 2009-04-02 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
JP4996241B2 (ja) 2003-01-14 2012-08-08 ギリアード サイエンシーズ， インコーポレイテッド 組み合わせ抗ウイルス治療のための組成物および方法
CN101068597B (zh) * 2004-09-02 2012-04-18 詹森药业有限公司 4-((4-((4-(2-氰基乙烯基)-2,6-二甲基苯基)氨基)-2-嘧啶基)氨基)苄腈的富马酸盐
WO2006024667A1 (en) * 2004-09-02 2006-03-09 Janssen Pharmaceutica N.V. Furamate of 4-( (4-( (4- (2-cyanoethenyl) -2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
CN104586850A (zh) * 2004-09-02 2015-05-06 詹森药业有限公司 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐
BRPI0514861A (pt) * 2004-09-02 2008-06-24 Janssen Pharmaceutica Nv furamato de 4-((4-((4-(2-cianoetenil)-2,6-dimetilfenil)amino)-2-pirimidi nil)amino)benzonitrila
PL1632232T6 (pl) * 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
TW201414495A (zh) * 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
ATE474560T1 (de) * 2005-12-14 2010-08-15 Cipla Ltd Pharmazeutische kombination aus nucleotid und nucleosid-reverse-transkriptase-hemmern (wie tenofovir und lamivudin) in verschiedenen teilen der dosiereinheit
PL1981506T6 (pl) * 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
FR2903312B1 (fr) 2006-07-05 2008-09-26 Univ Aix Marseille Ii Utilisation d'inhibiteurs d'hmg-coa reductase et de farnesyl-pyrophosphate synthase dans la preparation d'un medicament
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
PT2234620E (pt) * 2008-01-03 2016-06-20 Université D`Aix-Marseille Terapia tripla usada para o tratamento dum paciente infetado por hiv
NZ593950A (en) * 2008-12-24 2013-08-30 Janssen R & D Ireland Implantable devices for treating hiv
US8784858B2 (en) 2009-12-21 2014-07-22 Janssen R&D Ireland Degradable removable implant for the sustained release of an active compound
EA032868B1 (ru) 2010-01-27 2019-07-31 Вайв Хелткер Компани Комбинация для лечения вич-инфекции
EA201691695A1 (ru) * 2010-11-19 2017-11-30 Джилид Сайэнс, Инк. Терапевтические композиции, содержащие рилпивирин hcl и тенофовира дизопроксилфумарат
WO2012125993A1 (en) 2011-03-17 2012-09-20 Teva Pharmaceutical Industries Ltd. Solid state forms of rilpivirine base, and rilipivirine salts
WO2013038425A1 (en) * 2011-09-16 2013-03-21 Hetero Research Foundation Rilpivirine hydrochloride
MX344879B (es) 2012-12-21 2017-01-11 Gilead Sciences Inc Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
KR102606625B1 (ko) 2015-11-09 2023-11-27 길리애드 사이언시즈, 인코포레이티드 인간 면역결핍 바이러스의 치료를 위한 치료 조성물
HRP20240118T1 (hr) 2016-10-24 2024-04-12 Janssen Sciences Ireland Unlimited Company Disperzivni pripravci
WO2018119371A1 (en) * 2016-12-23 2018-06-28 Temple University - Of The Commonwealth System Of Higher Education Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis)
EP3612226A1 (en) * 2017-04-18 2020-02-26 Cipla Limited Combination therapy for use in treating retroviral infections
WO2019021319A1 (en) * 2017-07-27 2019-01-31 Cipla Limited PHARMACEUTICAL COMPOSITIONS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182111A (en) * 1987-11-17 1993-01-26 Boston University Research Foundation In vivo delivery of active factors by co-cultured cell implants
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5368864A (en) * 1988-11-25 1994-11-29 Henning Berlin Gmbh Chemie- Und Pharmawerk Formulation of oxypurinol and/or its alkali and alkaline earth salts
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
KR0172134B1 (ko) 1990-07-19 1999-02-01 오오쓰까 아끼히코 고형 제제
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5837747A (en) * 1991-10-29 1998-11-17 Vivorx, Inc. Crosslinkable polysaccharides, polycations and lipids useful for encapsulation and drug release
WO1993023021A2 (en) 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations
JPH06316524A (ja) 1992-09-11 1994-11-15 Naoyuki Inoue 抗エイズウイルス剤
TW401303B (en) 1994-07-01 2000-08-11 Janssen Pharmaceutica Nv Anti-HIV triple combination
IT1281502B1 (it) * 1995-06-13 1998-02-18 Sardinian Antiviral Research C Impiego di un inibitore non nucleosidico della trascrittasi inversa in associazione con inibitori nucleosidici per il trattamento della
US6045829A (en) * 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
CA2383233C (en) 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6743446B2 (en) * 1999-12-15 2004-06-01 The Ohio State University Research Foundation Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers
TWI284048B (en) * 2000-01-27 2007-07-21 Zentaris Ag Compressed microparticles for dry injection
EP1267879A2 (en) 2000-03-30 2003-01-02 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
DE10050199A1 (de) 2000-10-11 2002-04-25 Ethicon Gmbh Flächiges Implantat mit im Ultraschall detektierbaren Elementen
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
WO2003000235A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
CA2465779A1 (en) 2001-11-20 2003-05-30 Advanced Inhalation Research, Inc. Compositions for sustained action product delivery
AU2003266413B2 (en) 2002-08-09 2009-04-02 Janssen Pharmaceutica N.V. Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
AU2003278766A1 (en) * 2002-09-04 2004-03-29 Microchips, Inc. Method and device for the controlled delivery of parathyroid hormone
ATE361059T1 (de) 2002-11-08 2007-05-15 Glaxo Group Ltd Antivirale zusammensetzungen
WO2004046143A1 (en) 2002-11-15 2004-06-03 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
WO2004050068A1 (en) 2002-11-29 2004-06-17 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
KR20110132482A (ko) 2003-02-07 2011-12-07 얀센 파마슈티카 엔.브이. Ｈｉｖ 감염 예방용 피리미딘 유도체
KR100629771B1 (ko) * 2004-01-27 2006-09-28 씨제이 주식회사 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법
AR049297A1 (es) 2004-06-08 2006-07-12 Vertex Pharma Una composicion farmaceutica y dispersiones solidas de vx-950 (inhibidor de la proteasa de hcv ns3/4a) y proceso de obtencion
MY191349A (en) 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
CN104586850A (zh) 2004-09-02 2015-05-06 詹森药业有限公司 4-[[4-[[4-(2-氰基乙烯基)-2,6-二甲基苯基]氨基]-2-嘧啶基]氨基]苄腈的盐酸盐
EA200701065A1 (ru) 2004-11-16 2007-12-28 Элан Фарма Интернэшнл Лтд. Инъецируемые составы, содержащие нанодисперсный оланзапин
TW201414495A (zh) 2005-04-04 2014-04-16 Tibotec Pharm Ltd Ｈｉｖ-感染之預防
JP2008538754A (ja) * 2005-04-11 2008-11-06 ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ 薬剤を含んだ所定のレイヤパターンを有する複層構造体
AR056652A1 (es) 2005-04-11 2007-10-17 Tibotec Pharm Ltd Derivados de (1,10-b dihidro-2-(aminoalquil-fenil) -5h-pirazolo (1,5-c) (1,3)benzoxazin-5-il) fenilmetanona y su uso en la fabricacion de un medicamento
WO2006131806A2 (en) 2005-06-07 2006-12-14 Pfizer Products Inc. Multiparticulates comprising low-solubility drugs and carriers that result in rapid drug release
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
PL1981506T6 (pl) 2006-01-20 2021-07-12 Janssen Sciences Ireland Uc Długoterminowe leczenie zakażenia HIV z zastosowaniem TCM278
SI3366278T1 (sl) 2006-06-23 2024-12-31 Janssen Sciences Ireland Unlimited Company Vodne suspenzije tmc278
WO2008060360A2 (en) * 2006-09-28 2008-05-22 Surmodics, Inc. Implantable medical device with apertures for delivery of bioactive agents
TWI494133B (zh) 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
DK2175857T3 (da) 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
US20090123508A1 (en) 2007-10-04 2009-05-14 Boston Scientific Scimed, Inc. Implantable Drug Depot for Intrathecal Drug Delivery System for Pain Management
EP2358198A4 (en) * 2008-10-24 2012-11-14 Concert Pharmaceuticals Inc HYDROXYETHYLAMINO SULFONAMIDE DERIVATIVES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003016306A1 (en) * 2001-08-13 2003-02-27 Janssen Pharmaceutica N.V. Hiv inhibiting pyrimidines derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GILEAD SCIENCES INC.Gilead initiates study 934, a 48-weekclinicaltrialevaluatingVireadTM and EmtrivaTMversusCombivirTM.INTERNET ARTICLE [Online].2003,1-3. *
GILEADSCIENCESINC.Gileadinitiatesstudy934 a 48-weekclinicaltrialevaluatingVireadTM and EmtrivaTMversusCombivirTM.INTERNET ARTICLE [Online].2003
PAVIA AT.Abacavir/LamivudineinCombinationwithEfavirenz,Amprenavir/Ritonavir orStavudine.INTERNET ARTICLE[Online].2002,1. *
PAVIAAT.Abacavir/LamivudineinCombinationwithEfavirenz Amprenavir/Ritonavir orStavudine.INTERNET ARTICLE[Online].2002

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166952B2 (en) 2019-11-29 2021-11-09 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer
US11571422B2 (en) 2019-11-29 2023-02-07 Scipio Life Sciences Limited Composition including rilpivirine and method for treating tumors or cancer
US12023334B2 (en) 2019-11-29 2024-07-02 Aptorum Therapeutics Limited Composition including rilpivirine and method for treating tumors or cancer

Also Published As

Publication number Publication date
FR16C1022I1 (fr) 2017-02-03
CY2016049I2 (el) 2017-07-12
AP2006003551A0 (en) 2006-04-30
MXPA06002437A (es) 2006-06-20
CY2016049I1 (el) 2017-07-12
NO2016025I1 (enExample) 2016-12-20
HUS1500052I1 (hu) 2016-03-29
CY2015039I1 (el) 2016-08-31
NL300781I2 (enExample) 2016-04-19
US20080200435A1 (en) 2008-08-21
NO2016026I1 (no) 2016-12-20
PL1663240T5 (pl) 2024-02-26
IL213104A0 (en) 2011-07-31
US20180228800A1 (en) 2018-08-16
CY2015040I1 (el) 2016-08-31
CY2015039I2 (el) 2016-08-31
IL173438A (en) 2012-03-29
KR20060090658A (ko) 2006-08-14
FR15C0071I1 (enExample) 2015-04-12
FR15C0073I1 (enExample) 2015-04-12
IL173438A0 (en) 2006-06-11
JP2007520443A (ja) 2007-07-26
NO2014030I1 (no) 2015-01-05
IL213104A (en) 2016-02-29
HUS1500053I1 (hu) 2016-03-29
US20100029591A1 (en) 2010-02-04
AU2014203484A1 (en) 2014-07-17
JP2012051915A (ja) 2012-03-15
NO20061374L (no) 2006-03-27
US20200171027A1 (en) 2020-06-04
CY2015040I2 (el) 2016-08-31
AU2004268390B2 (en) 2011-03-31
NZ545306A (en) 2009-11-27
NO2014032I2 (no) 2014-12-18
BE2015C053I2 (enExample) 2023-12-14
NO2014030I2 (no) 2014-12-18
MY169670A (en) 2019-05-08
LTPA2016044I1 (lt) 2017-01-10
FI1663240T4 (fi) 2023-04-25
NO2014031I1 (no) 2015-01-05
LTC1663240I2 (lt) 2022-05-25
AU2004268390A1 (en) 2005-03-10
JP5507791B2 (ja) 2014-05-28
US20150283135A1 (en) 2015-10-08
CY2015038I2 (el) 2016-08-31
FR15C0072I1 (enExample) 2015-04-12
US20190216807A1 (en) 2019-07-18
US8841310B2 (en) 2014-09-23
PL1663240T3 (pl) 2015-10-30
JP2015044839A (ja) 2015-03-12
AU2011201123B2 (en) 2013-10-10
CY2015038I1 (el) 2016-08-31
NO334877B1 (no) 2014-06-23
HUS1500054I1 (hu) 2016-03-29
HUS1600058I1 (hu) 2017-02-28
CY2016048I2 (el) 2017-07-12
EP1663240B2 (en) 2023-03-01
AU2014203484B2 (en) 2016-09-29
NL300768I2 (nl) 2023-08-09
CY2016048I1 (el) 2017-07-12
NL300781I1 (enExample) 2016-04-19
AU2011201123A1 (en) 2011-04-07
LU92855I2 (fr) 2015-12-21
AU2019200813A1 (en) 2019-02-28
US20220008417A1 (en) 2022-01-13
FR15C0071I2 (fr) 2016-02-12
AU2016210733B2 (en) 2018-11-08
EP1663240A1 (en) 2006-06-07
EP1663240B1 (en) 2015-04-22
WO2005021001A1 (en) 2005-03-10
US20140349971A1 (en) 2014-11-27
FR15C0072I2 (fr) 2019-05-17
FR16C1024I1 (fr) 2017-02-03
JP5820045B2 (ja) 2015-11-24
HUS1600059I1 (hu) 2017-02-28
CA2537095A1 (en) 2005-03-10
AU2016210733A1 (en) 2016-08-25
LTPA2016045I1 (lt) 2017-01-10
CA2537095C (en) 2012-05-29
NO2014032I1 (no) 2015-01-05
LU92854I2 (fr) 2015-12-21
US20170100398A1 (en) 2017-04-13
FR15C0073I2 (fr) 2016-02-12
HRP20150798T1 (hr) 2015-09-11
HRP20150798T4 (hr) 2023-06-09
NL300768I1 (enExample) 2015-12-16
HK1092698A1 (en) 2007-02-16
LU92853I2 (fr) 2015-12-21
AP2109A (en) 2010-02-26
NO2014031I2 (no) 2014-12-18
CN101060844A (zh) 2007-10-24

Similar Documents

Publication Publication Date Title
CN101060844B (zh) 包含嘧啶的nnrti和rt抑制剂的组合
KR101524165B1 (ko) Ｈｉｖ 인테그라제 억제제의 약동학을 개선하기 위한 방법
KR101539245B1 (ko) 피리미딘 함유 ｎｎｒｔｉ와 ｒｔ 저해제의 배합물
HK1165277A (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
HK1092698B (en) Combinations of a pyrimidine containing nnrti with rt inhibitors
ZA200601820B (en) Combinations of a pyrimidine containing NNRTI with RT inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: IRELAND JANSSEN R + D COMPANY

Free format text: FORMER OWNER: JANSSEN R + D IRELAND

Effective date: 20150723

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee

Owner name: TIBOTEC PHARM LTD.

Free format text: FORMER NAME: TIBOTEC NV

Owner name: JANSSEN R + D IRELAND

Free format text: FORMER NAME: TIBOTEC PHARM LTD.

CP01 Change in the name or title of a patent holder

Address after: The Irish Village

Patentee after: JANSSEN R&D IRELAND

Address before: The Irish Village

Patentee before: TIBOTEC PHARMACEUTICALS

Address after: The Irish Village

Patentee after: TIBOTEC PHARMACEUTICALS

Address before: The Irish Village

Patentee before: TIBOTEC PHARMACEUTICALS Ltd.

TR01 Transfer of patent right

Effective date of registration: 20150723

Address after: The Irish Village

Patentee after: JANSSEN R&D IRELAND

Address before: The Irish Village

Patentee before: JANSSEN R&D IRELAND

CX01 Expiry of patent term

Granted publication date: 20120104

CX01 Expiry of patent term